We are pleased to announce that we now accept all major credit cards, as well as HSA and FSA for payment!
Reduced bone density means the bones contain less mineral and may be weaker than expected. It often develops without pain or obvious symptoms, which is why many women do not know bone loss is occurring until it appears on a bone density test or a fracture happens.
Low bone density treatment depends on more than one test result.
Age, menopause status, previous fractures, medications, medical conditions, family history, and overall fracture risk all help determine whether a woman needs monitoring, lifestyle changes, medication, or specialist care.
Optimal Female Wellness helps patients review factors that may affect bone health and determine whether nutrition support, menopause care, medication management, bone density testing, or referral may be appropriate.
Bone is living tissue that is constantly being broken down and rebuilt.
During younger adulthood, the body generally replaces old bone efficiently. With age, bone breakdown can begin to outpace new bone formation.
ACOG explains that this shift becomes particularly important around menopause because estrogen helps protect against bone loss. The decline in estrogen can trigger a period of faster bone loss beginning around the final menstrual period.
Reduced bone density usually does not cause pain by itself.
Symptoms such as:
may appear only after vertebral fractures have already occurred.
A fracture after a relatively minor fall or impact may also be the first indication that bones have become fragile.
Bone density exists on a spectrum.
Osteopenia, also called low bone mass, means bone density is lower than expected but has not reached the diagnostic threshold for osteoporosis.
Osteoporosis describes more substantial bone loss and an increased risk of fracture.
For postmenopausal women, DXA results are commonly classified using a T-score:
These thresholds are used for diagnostic classification, but fracture risk is not determined by T-score alone. Some women with osteopenia still have a high enough fracture risk to need treatment.
Women who experience menopause earlier than expected may have a longer period of life with lower estrogen exposure.
ACOG notes that early menopause can increase the risk of losing bone density and that hormone therapy is often considered in appropriate patients until around the average age of natural menopause.
The decision still depends on individual medical history and contraindications.
Early menopause should also prompt consideration of:
Risk may increase with:
Certain medical conditions may also contribute, including:
Certain seizure medications, cancer therapies, corticosteroids, and other prescriptions may affect bone health as well.
Medication history should therefore be part of every bone-risk evaluation.
Women who experience menopause earlier than expected may have a longer period of life with lower estrogen exposure.
ACOG notes that early menopause can increase the risk of losing bone density and that hormone therapy is often considered in appropriate patients until around the average age of natural menopause.
The decision still depends on individual medical history and contraindications.
Early menopause should also prompt consideration of:
The standard bone density test is a dual-energy X-ray absorptiometry scan, commonly called a DXA or DEXA scan.
DXA uses low-dose X-rays to measure bone mineral density.
Testing commonly focuses on areas where osteoporotic fractures are important, such as:
The test is quick and noninvasive.
It does not directly measure bone strength, but bone mineral density is an important predictor of fracture risk.
The current USPSTF recommendation is to screen all women age 65 and older for osteoporosis.
Postmenopausal women younger than 65 may also benefit from screening when they have one or more risk factors for osteoporosis.
USPSTF suggests first reviewing risk factors such as:
A fracture-risk assessment tool can then help determine whether DXA screening may be appropriate.
Women with secondary causes of bone loss or chronic medication exposure may need individualized screening outside these routine recommendations.
A fragility fracture is a fracture that occurs from an injury that would not normally break healthy bone.
Examples may include:
Common osteoporotic fracture sites include:
A previous fragility fracture is one of the strongest indicators of future fracture risk.
The Endocrine Society recommends pharmacologic treatment for postmenopausal women at high fracture risk, especially those who have recently experienced a fracture.
A T-score does not capture every factor that determines whether someone is likely to fracture a bone.
Clinical risk may also reflect:
Risk-assessment tools such as FRAX may help estimate the probability of major osteoporotic and hip fractures over a specified period.
These tools do not replace clinical judgment.
They add context to the DXA result so treatment decisions are based on actual fracture risk rather than a single cutoff.
Not every woman with osteopenia needs prescription medication.
Treatment depends on:
A lower-risk patient may need monitoring and foundational bone-health strategies.
Someone with osteoporosis, a fragility fracture, or high calculated fracture risk may need prescription therapy.
The purpose is to prevent fractures, not simply make the DXA number look better.
Bone responds to physical loading.
Weight-bearing activity may include:
Resistance exercise can also help maintain muscle and provide mechanical loading to the skeleton.
Maintaining strength is important because stronger muscles can improve balance and reduce fall risk.
Exercise should still match the patient’s health and fracture risk.
Women with significant osteoporosis, vertebral fractures, balance problems, or severe joint disease may need professional guidance before beginning high-impact activity or exercises involving substantial spinal bending or twisting.
Preventing fractures involves more than increasing bone density.
Falls are a major cause of osteoporotic fractures.
Fall-risk reduction may involve:
A woman with relatively low bone density but frequent falls may face substantial fracture risk.
Bone strength and fall risk should therefore be considered together.
Prescription treatment may be appropriate for women with:
Medication selection depends on:
Different medications work in different ways.
Some slow bone breakdown, while others help stimulate new bone formation.
Testosterone therapy is not an established treatment for osteopenia or osteoporosis in women.
It should not be prescribed solely to:
Women with reduced bone density should receive evidence-based fracture-risk evaluation and treatment rather than relying on testosterone as a substitute for established osteoporosis care.
When bone density is unexpectedly low, particularly in a younger woman, an underlying medical condition may need evaluation.
Possible contributors include:
Laboratory evaluation may be individualized according to the clinical picture.
The goal is not only to treat low bone density but also to identify any condition that is continuing to weaken bone.
Reduced bone density usually develops silently, but screening and early risk assessment can identify problems before a fracture affects mobility and independence.
Optimal Female Wellness helps patients consider menopause-related bone changes, nutrition, medications, fracture risk, and other factors that may affect bone health.
Schedule an appointment to discuss your risk factors, previous bone-density results, menopause history, medications, and whether DXA testing, nutritional support, menopause care, medication management, or specialist coordination may be appropriate.
Reduced bone density means the bones contain less mineral than expected and may be less resistant to fracture. Depending on severity, it may be described as osteopenia or osteoporosis.
Usually not. Bone loss often develops silently. Back pain, height loss, or posture changes may occur after vertebral fractures, and a fragility fracture may be the first sign of osteoporosis.
In postmenopausal women, a T-score between -1.0 and -2.5 is generally classified as osteopenia. A T-score of -2.5 or below is consistent with osteoporosis.
DXA testing measures bone mineral density, usually at the hip and spine. Results are interpreted alongside age, previous fractures, medications, menopause status, and overall fracture risk.
No. Some women need monitoring, nutrition, exercise, and fall-prevention strategies. Medication may be recommended when overall fracture risk is high.
Yes. Declining estrogen around menopause can accelerate bone loss, particularly during the years surrounding the final menstrual period.
Yes. Systemic hormone therapy can reduce early postmenopausal bone loss and fracture risk while it is being used, but it is not appropriate for every patient.
Calcium and vitamin D support bone health but generally do not replace osteoporosis medication when fracture risk is high. Appropriate intake is important, but excessive supplementation is not necessarily beneficial.
USPSTF recommends screening all women age 65 and older. Postmenopausal women younger than 65 may also need DXA screening when risk factors indicate increased fracture risk.
Treatment may include adequate calcium and vitamin D, weight-bearing and resistance activity, fall prevention, menopause care, treatment of underlying conditions, and prescription osteoporosis medication when fracture risk warrants it.